Tharimmune, Inc. | WebDisclosure

Switch to English

8205	Sociétés
109437	Mots-clés
51603	Articles
60273	Communiqués

Accueil
Sociétés
Tharimmune, Inc.

COMMUNIQUÉ DE PRESSE

publié le 20/02/2024 à 14:01, il y a 8 mois 13 jours

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Tharimmune, Inc. announces successful Phase 1 trial completion for TH104, a promising treatment for chronic pruritus in primary biliary cholangitis. The study shows positive safety and tolerability profile aligned with previous findings

Tharimmune Inc. TH104 Phase 1 Trial Chronic Pruritus Primary Biliary Cholangitis
BRÈVE

publiée le 20/02/2024 à 14:01, il y a 8 mois 13 jours

Tharimmune announces positive Phase 1 results for TH104 and funding until 2025

Biotechnology Phase 1 Clinical Trial Funding TH104 Primary Biliary Cholangitis
BRÈVE

publiée le 20/02/2024 à 14:01, il y a 8 mois 13 jours

Tharimmune annonce les résultats positifs de la Phase 1 pour TH104 et le financement jusqu'en 2025

Biotechnologie Financement TH104 Essai Clinique De Phase 1 Cholangite Biliaire Primitive
COMMUNIQUÉ DE PRESSE

publié le 05/02/2024 à 14:30, il y a 8 mois 28 jours

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. completes first patient dosing in Phase 1 clinical trial for TH104, an oral thin film targeting liver-related and pruritogenic inflammatory conditions. Topline data expected in 2Q24 with full readout shortly after. Company fully funded into 2025 for Phase 1 and 2 readouts

Phase 1 Clinical Trial Tharimmune Inc. TH104 Liver-related Conditions Pruritogenic Inflammatory Conditions
COMMUNIQUÉ DE PRESSE

publié le 29/01/2024 à 14:00, il y a 9 mois 6 jours

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025

Tharimmune Inc. TH104 Phase 1 Trial Buccal Film Chronic Pruritus
COMMUNIQUÉ DE PRESSE

publié le 11/12/2023 à 14:01, il y a 10 mois 24 jours

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
COMMUNIQUÉ DE PRESSE

publié le 27/11/2023 à 14:00, il y a 11 mois 7 jours

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Les Echos

Publié le 04/11/2024 à 18:13, il y a 11 heures 8 minutes

Thales : lancement de l’opération 2024 d’actionnariat salarié
Publié le 04/11/2024 à 18:13, il y a 11 heures 8 minutes

Thales: Launch of the 2024 Employee Share Ownership Plan
Publié le 04/11/2024 à 18:11, il y a 11 heures 9 minutes

Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Publié le 04/11/2024 à 18:11, il y a 11 heures 9 minutes

Déclaration mensuelle des actions et droits de vote – 31/10/2024
Publié le 04/11/2024 à 17:45, il y a 11 heures 36 minutes

Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 05/11/2024 à 03:30, il y a 1 heure 51 minutes

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Publié le 05/11/2024 à 00:00, il y a 5 heures 21 minutes

Axcap Ventures Announces Upsizing of Private Placement
Publié le 04/11/2024 à 23:00, il y a 6 heures 21 minutes

Jericho Energy Ventures Announces Plan to Separate Hydrogen Platform from Traditional Energy Assets to Maximize Shareholder Value
Publié le 04/11/2024 à 23:00, il y a 6 heures 21 minutes

APEX/IFSA Global EXPO Showcases the Future of Aviation With Nearly 3,000 Industry ‎Professionals in Attendance
Publié le 04/11/2024 à 22:45, il y a 6 heures 36 minutes

Alphinat Announces a Profit of $160,597 for Fiscal Year Ended August 31, 2023

Voir tout ACCESSWIRE

EQS Group

Publié le 04/11/2024 à 22:20, il y a 7 heures 1 minute

Adler Group S.A. announces the sale of its 62.78% stake in Brack Capital Properties N.V. to LEG Immobilien SE
Publié le 04/11/2024 à 21:15, il y a 8 heures 6 minutes

EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Publié le 04/11/2024 à 19:00, il y a 10 heures 21 minutes

EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Publié le 04/11/2024 à 19:00, il y a 10 heures 21 minutes

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Publié le 04/11/2024 à 19:00, il y a 10 heures 21 minutes

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF